万邦德：公司在研的小分子多肽新药在肥胖、糖尿病等适应症领域处于临床前阶段

Core Viewpoint - Wanbangde (002082) is advancing a small molecule peptide new drug targeting obesity and diabetes, currently in the preclinical stage with promising preliminary data, and plans to move towards clinical translation [1] Group 1: Drug Development - The small molecule peptide new drug is in the preclinical stage for indications such as obesity and diabetes [1] - Preliminary data shows that the drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, has anti-inflammatory effects, and improves multiple metabolic indicators [1] - In studies involving diabetic obese mice, the weight loss efficiency of this drug significantly outperformed that of Semaglutide, a GLP-1 class drug [1] Group 2: Mechanism of Action - The drug has a different target and mechanism of action compared to GLP-1 drugs like Semaglutide [1]